Open AccessStudy on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial
Author(s) -
Kangxin Wang,
Ting-Yun Cui,
Xudong Yang,
Guo-Qun Wang,
Qiu-Sheng Jiang,
Hui Sun,
Nanyuan Jiang,
Xiao-Min Yong,
Chao Shi,
Ye Ding,
Xiaofeng Chen,
Yueyu Fang
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s316288
Subject(s) - apatinib , medicine , regimen , oncology , clinical endpoint , discontinuation , oxaliplatin , chemotherapy , cancer , chemotherapy regimen , surgery , clinical trial , colorectal cancer
The standard treatment for advanced gastric/gastroesophageal junction cancer (AGC/GEJC) is palliative chemotherapy combined with targeted therapy. The SOX regimen (S-1 plus oxaliplatin) is recommended as neoadjuvant or palliative first-line chemotherapy in Asian patients. Apatinib, an oral VEGFR tyrosine kinase inhibitor, is associated with additional survival benefit as third- or subsequent-line therapy. However, the median overall survival time of AGC/GEJC is only 8-11 months in the West and 13-17 months in East Asia/Japan, even with the application of anti-angiogenic agents. Hence, the multimodal and individual management of patients is challenging standards to improve prognosis, including the preferential use of low-dose anti-angiogenic drugs and immunotherapy, as well as the application of multi-disciplinary treatment (MDT)-directed conversion therapy.